HIT211504993 是一种选择性组蛋白去乙酰化酶 6 (HDAC6) 抑制剂(IC50 为 0.070 μM),可抑制癌细胞增殖、引发 G1 期细胞周期阻滞并诱导细胞凋亡 (apoptosis),并通过核质乙酰化、p53 调控及 Wnt/β-catenin 信号通路调控抑制 Myc 驱动的肿瘤发生,同时可抑制结肠癌异种移植小鼠模型中的肿瘤生长,因此可用于结肠癌的相关研究。
HIT211504993
产品编号: MS-D26400 分子式: C23H27ClN2O6S 分子量: 494.99
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

HIT211504993 是一种选择性组蛋白去乙酰化酶 6 (HDAC6) 抑制剂(IC50 为 0.070 μM),可抑制癌细胞增殖、引发 G1 期细胞周期阻滞并诱导细胞凋亡 (apoptosis),并通过核质乙酰化、p53 调控及 Wnt/β-catenin 信号通路调控抑制 Myc 驱动的肿瘤发生,同时可抑制结肠癌异种移植小鼠模型中的肿瘤生长,因此可用于结肠癌的相关研究。

生物实验数据

生物活性 HIT211504993 is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 0.070 μM that inhibits cancer cell proliferation, induces G1 cell cycle arrest and apoptosis, suppresses Myc-driven tumorigenesis through nucleocytoplasmic acetylation, p53 regulation, and Wnt/β-catenin signaling pathway modulation, and inhibits tumor growth in a mouse model of colon cancer xenografts, making it useful for research related to colon cancer.
IC50 & Target

HDAC6

0.07 μM (IC50)

体外研究
(In Vitro)

HIT211504993 可强效且选择性地抑制 HDAC6,其 IC50 为 0.070 ± 0.002 μM,对 HDAC6 的抑制活性比对 HDAC2 高约 89 倍,比对 HDAC4 高约 486 倍。
HIT211504993 (48 h) 可选择性抑制结直肠癌细胞 (HCT-8、HCT116) (IC50 值为 12.483 和 18.840 μM) 及其他肿瘤细胞系的活力,对正常 NCM460 肠上皮细胞的毒性较低。
HIT211504993 (10-50 μM; 12-48 h) 可以浓度和时间依赖的方式有效增强 HCT-8 和 HCT116 结直肠癌细胞中组蛋白 H3 和非组蛋白 α-微管蛋白的乙酰化水平。
HIT211504993 (20 μM; 24 h) 可抑制 HCT-8 和 HCT116 结直肠癌细胞的长期增殖能力,这可通过克隆形成能力降低来验证。
HIT211504993 (20 μM; 12-48 h) 可在 HCT-8 和 HCT116 结直肠癌细胞中诱导 G1 期细胞周期阻滞并下调 Cyclin D 的表达,从而抑制细胞增殖。
HIT211504993 (20 μM; 12-48 h) 可通过内源性线粒体通路在 HCT-8 和 HCT116 结直肠癌细胞中诱导时间依赖性细胞凋亡,Bcl-2/Bax 表达改变及 Annexin V 阳性细胞增加可证明这一点。
HIT211504993 (60 μM; 6 h) 可在 HCT-8 结直肠癌细胞中直接结合 HDAC1 和 HDAC2,提高二者的热稳定性。
HIT211504993 (20 μM; 4-24 h) 可调控 HCT-8 结直肠癌细胞的基因表达,下调 MYC 和 Wnt/β-catenin 通路组分,同时上调 p53 和 DUSP1,从而抑制肿瘤发生。

Cell Viability Assay

Cell Line: HCT-8, HCT116, NCM460, A2780, A549, MDA-MB-231, HepG2, HeLa, A375 cells
Concentration: 0.5-100 μM
Incubation Time: 48 h
Result: Exhibited an IC50 of 12.483 ± 0.92 μM in HCT-8 cells.
Exhibited an IC50 of 18.840 ± 0.88 μM in HCT116 cells.
Exhibited an IC50 of 46.043 ± 3.39 μM in NCM460 cells.
Exhibited an IC50 of 33.080 ± 3.98 μM in A2780 cells.
Exhibited an IC50 of 25.967 ± 5.45 μM in A549 cells.
Exhibited an IC50 of 10.782 ± 0.76 μM in MDA-MB-231 cells.
Exhibited an IC50 of 26.680 ± 1.75 μM in HepG2 cells.
Exhibited an IC50 of 56.557 ± 3.74 μM in HeLa cells.
Exhibited an IC50 of 20.983 ± 0.48 μM in A375 cells.

Western Blot Analysis

Cell Line: HCT-8, HCT116 colorectal cancer cells
Concentration: 10, 20, 30, 40,50 μM
Incubation Time: 12, 24, 36, 48 h
Result: Increased acetyl-H3 and acetyl-α-tubulin levels in both cell lines, with the most substantial enhancement at 20 μM.
Induced time-dependent increases in acetyl-H3 and acetyl-α-tubulin levels in both cell lines when incubated for 12-48 h at 20 μM.

Cell Cycle Analysis

Cell Line: HCT-8, HCT116 colorectal cancer cells
Concentration: 20 μM
Incubation Time: 12, 24, 36, 48 h
Result: Induced G1 phase cell cycle arrest in both HCT-8 and HCT116 cells.
Caused a significant decrease in Cyclin D protein expression in a time-dependent manner.

Apoptosis Analysis

Cell Line: HCT-8, HCT116 colorectal cancer cells
Concentration: 20 μM
Incubation Time: 12, 24, 36, 48 h
Result: Induced apoptosis in a time-dependent manner, with progressive increases in apoptotic cell proportions over 12-48 h.
Downregulated anti-apoptotic Bcl-2 protein expression in both cell lines.
Upregulated pro-apoptotic Bax protein expression in both cell lines.

Real Time qPCR

Cell Line: HCT-8 colorectal cancer cells
Concentration: 20 μM
Incubation Time: 4, 12, 24 h
Result: Altered the expression of 2692, 4788, and 5627 differentially expressed genes at 4, 12, and 24 h respectively, with enrichment in histone modification, cell cycle arrest, p53 signaling, and Wnt/β-catenin signaling pathways.
Induced time-dependent downregulation of MYC mRNA and protein expression.
Induced upregulation of DUSP1 and p53 mRNA and protein expression.
Downregulated mRNA levels of Wnt4, β-catenin, TCF4, and LEF1.
Reduced β-catenin protein expression in HCT-8 cells.
体内研究
(In Vivo)

HIT211504993 (25-100 mg/kg;腹腔注射;每天一次;15 天) 可呈剂量依赖性抑制 HCT-8 结直肠癌异种移植瘤的生长,在 50 mg/kg 剂量下肿瘤体积缩小率达 77%,且耐受性良好。

Animal Model: BALB/c nude (4−6 weeks old, 16−20 g, subcutaneous xenograft via HCT-8 cell injection)
Dosage: 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: I.p.; daily; 15 days
Result: Reduced tumor weight relative to vehicle control at 25 mg/kg.
Reduced tumor volume by 77% and tumor weight by 68% relative to vehicle control at 50 mg/kg.
Suppressed tumor growth to a greater extent than the 50 mg/kg dose at 100 mg/kg.
Caused no significant body weight changes or histological abnormalities in heart, liver, spleen, kidneys, or lungs across all treatment doses.

化学信息

分子量 494.99
分子式 C23H27ClN2O6S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础